Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study
Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single‐cell molecular analysis is required. We developed the ChimeraX(®)‐i120 platform to facilitate negative enrichment, immun...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410565/ https://www.ncbi.nlm.nih.gov/pubmed/33301640 http://dx.doi.org/10.1002/1878-0261.12876 |
_version_ | 1783747139428417536 |
---|---|
author | Wang, Peng‐Xiang Sun, Yun‐Fan Jin, Wei‐Xiang Cheng, Jian‐Wen Peng, Hai‐Xiang Xu, Yang Zhou, Kai‐Qian Chen, Li‐Meng Huang, Kai Wu, Sui‐Yi Hu, Bo Zhang, Ze‐Fan Guo, Wei Cao, Ya Zhou, Jian Fan, Jia Yang, Xin‐Rong |
author_facet | Wang, Peng‐Xiang Sun, Yun‐Fan Jin, Wei‐Xiang Cheng, Jian‐Wen Peng, Hai‐Xiang Xu, Yang Zhou, Kai‐Qian Chen, Li‐Meng Huang, Kai Wu, Sui‐Yi Hu, Bo Zhang, Ze‐Fan Guo, Wei Cao, Ya Zhou, Jian Fan, Jia Yang, Xin‐Rong |
author_sort | Wang, Peng‐Xiang |
collection | PubMed |
description | Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single‐cell molecular analysis is required. We developed the ChimeraX(®)‐i120 platform to facilitate negative enrichment, immunofluorescent labeling, and machine learning‐based identification of CTCs. Analytical performances were evaluated, and a total of 477 participants were enrolled to validate the clinical feasibility of ChimeraX(®)‐i120 CTC detection. We analyzed copy number alteration profiles of isolated single cells. The ChimeraX(®)‐i120 platform had high sensitivity, accuracy, and reproducibility for CTC detection. In clinical samples, an average value of > 60% CTC‐positive rate was found for five cancer types (i.e., liver, biliary duct, breast, colorectal, and lung), while CTCs were rarely identified in blood from healthy donors. In hepatocellular carcinoma patients treated with curative resection, CTC status was significantly associated with tumor characteristics, prognosis, and treatment response (all P < 0.05). Single‐cell sequencing analysis revealed that heterogeneous genomic alteration patterns resided in different cells, patients, and cancers. Our results suggest that the use of this ChimeraX(®)‐i120 platform and the integrated workflow has validity as a tool for CTC detection and downstream genomic profiling in the clinical setting. |
format | Online Article Text |
id | pubmed-8410565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84105652021-09-03 Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study Wang, Peng‐Xiang Sun, Yun‐Fan Jin, Wei‐Xiang Cheng, Jian‐Wen Peng, Hai‐Xiang Xu, Yang Zhou, Kai‐Qian Chen, Li‐Meng Huang, Kai Wu, Sui‐Yi Hu, Bo Zhang, Ze‐Fan Guo, Wei Cao, Ya Zhou, Jian Fan, Jia Yang, Xin‐Rong Mol Oncol Research Articles Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single‐cell molecular analysis is required. We developed the ChimeraX(®)‐i120 platform to facilitate negative enrichment, immunofluorescent labeling, and machine learning‐based identification of CTCs. Analytical performances were evaluated, and a total of 477 participants were enrolled to validate the clinical feasibility of ChimeraX(®)‐i120 CTC detection. We analyzed copy number alteration profiles of isolated single cells. The ChimeraX(®)‐i120 platform had high sensitivity, accuracy, and reproducibility for CTC detection. In clinical samples, an average value of > 60% CTC‐positive rate was found for five cancer types (i.e., liver, biliary duct, breast, colorectal, and lung), while CTCs were rarely identified in blood from healthy donors. In hepatocellular carcinoma patients treated with curative resection, CTC status was significantly associated with tumor characteristics, prognosis, and treatment response (all P < 0.05). Single‐cell sequencing analysis revealed that heterogeneous genomic alteration patterns resided in different cells, patients, and cancers. Our results suggest that the use of this ChimeraX(®)‐i120 platform and the integrated workflow has validity as a tool for CTC detection and downstream genomic profiling in the clinical setting. John Wiley and Sons Inc. 2020-12-25 2021-09 /pmc/articles/PMC8410565/ /pubmed/33301640 http://dx.doi.org/10.1002/1878-0261.12876 Text en © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Wang, Peng‐Xiang Sun, Yun‐Fan Jin, Wei‐Xiang Cheng, Jian‐Wen Peng, Hai‐Xiang Xu, Yang Zhou, Kai‐Qian Chen, Li‐Meng Huang, Kai Wu, Sui‐Yi Hu, Bo Zhang, Ze‐Fan Guo, Wei Cao, Ya Zhou, Jian Fan, Jia Yang, Xin‐Rong Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study |
title | Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study |
title_full | Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study |
title_fullStr | Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study |
title_full_unstemmed | Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study |
title_short | Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study |
title_sort | circulating tumor cell detection and single‐cell analysis using an integrated workflow based on chimerax(®)‐i120 platform: a prospective study |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410565/ https://www.ncbi.nlm.nih.gov/pubmed/33301640 http://dx.doi.org/10.1002/1878-0261.12876 |
work_keys_str_mv | AT wangpengxiang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT sunyunfan circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT jinweixiang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT chengjianwen circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT penghaixiang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT xuyang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT zhoukaiqian circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT chenlimeng circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT huangkai circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT wusuiyi circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT hubo circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT zhangzefan circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT guowei circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT caoya circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT zhoujian circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT fanjia circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT yangxinrong circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy |